XHKG
0575
Market cap32mUSD
Oct 09, Last price
0.88HKD
1D
-0.57%
1Q
-6.91%
Jan 2017
-92.58%
Name
Endurance RP Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Regent Pacific Group Limited is an investment holding company that primarily focuses on the healthcare and life sciences sectors. The company is involved in the research, development, and sale of pharmaceutical products, with a notable focus on treatments for urological disorders. It also invests in a portfolio of both listed and unlisted corporate entities.
Key people
Jamie Alexander Gibson
Chief Executive Officer, Executive Director · since 2002
Yuk Bing Fung
Company Secretary
Non-Executive Director · since 2000
Charles David Andrew Comba
Independent Non-executive Director · since 2005
Julie Oates
Independent Non-Executive Director · since 2004
Stawell Mark Searle
Independent Non-Executive Director · since 2001
Headquarters & legal address
C/O MAPLES COROPORATE SERVICES LIMITED
PO BOX 309 UGLAND HOUSE
SOUTH CHURCH STREET
GEORGE TOWN KY1-1104
KY
PO BOX 309 UGLAND HOUSE
SOUTH CHURCH STREET
GEORGE TOWN KY1-1104
KY
Previous name
ENDURANCE RP LIMITED
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||